{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:09:54Z","timestamp":1791684594586,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.semarthrit.2017.10.010","type":"journal-article","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T02:48:50Z","timestamp":1508122130000},"page":"858-864","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis"],"prefix":"10.1016","volume":"47","author":[{"given":"Adam","family":"Schiffenbauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Pokrovnichka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galen","family":"Joe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Shrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imelda Victoria","family":"Cabalar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Faghihi-Kashani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael O.","family":"Harris-Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.","family":"Plotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick W.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2017.10.010_bib1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/00002281-200111000-00005","article-title":"Effect of tumor necrosis factor-alpha on skeletal muscle metabolism","volume":"13","author":"Li","year":"2001","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/1759720X12447705","article-title":"Novel approaches in the treatment of myositis and myopathies","volume":"4","author":"Albayda","year":"2012","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/BOR.0b013e328358ac72","article-title":"Therapeutic advances in myositis","volume":"24","author":"Aggarwal","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.semarthrit.2006.07.003","article-title":"Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implications","volume":"36","author":"Efthimiou","year":"2006","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib5","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2007.077974","article-title":"A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies","volume":"67","author":"Dastmalchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000070852","article-title":"Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations","volume":"50","author":"Hengstman","year":"2003","journal-title":"Eur Neurol"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib7","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2005.048744","article-title":"Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients","volume":"65","author":"Efthimiou","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib8","first-page":"637452","article-title":"TNF-alpha in the locomotor system beyond joints: high degree of involvement in myositis in a rabbit model","volume":"2012","author":"Forsgren","year":"2012","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s004010051165","article-title":"Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis","volume":"99","author":"Kuru","year":"2000","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib10","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00296-010-1692-y","article-title":"Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity","volume":"32","author":"Mielnik","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s100670070027","article-title":"Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis","volume":"19","author":"Shimizu","year":"2000","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0165-5728(95)00122-0","article-title":"Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls","volume":"63","author":"Lundberg","year":"1995","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0960-8966(98)00126-6","article-title":"Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies","volume":"9","author":"De Bleecker","year":"1999","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib14","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/art.1780371206","article-title":"Elevated serum levels of interleukin-1 receptor antagonist in polymyositis\/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response","volume":"37","author":"Gabay","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib15","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/art.1780400514","article-title":"Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies","volume":"40","author":"Lundberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1523-1747.2002.01869.x","article-title":"Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis","volume":"119","author":"Werth","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib17","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00005072-199603000-00009","article-title":"Cytokine expression profile in idiopathic inflammatory myopathies","volume":"55","author":"Tews","year":"1996","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00401-002-0635-4","article-title":"Expression of tumor necrosis factor-alpha in regenerating muscle fibers in inflammatory and non-inflammatory myopathies","volume":"105","author":"Kuru","year":"2003","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1756-185X.2011.01654.x","article-title":"Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients","volume":"15","author":"Higgs","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib20","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/1529-0131(200010)43:10<2368::AID-ANR26>3.0.CO;2-8","article-title":"TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications","volume":"43","author":"Pachman","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib21","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/art.20208","article-title":"Association of the proinflammatory haplotype (MICA5.1\/TNF2\/TNFa2\/DRB1*03) with polymyositis and dermatomyositis","volume":"50","author":"Hassan","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/joim.12524","article-title":"Diagnosis and classification of idiopathic inflammatory myopathies","volume":"280","author":"Lundberg","year":"2016","journal-title":"J Intern Med"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib25","first-page":"603","article-title":"Defining clinical improvement in adult and juvenile myositis","volume":"30","author":"Rider","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20035","article-title":"Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies","volume":"62","author":"Rider","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"Suppl. 11","key":"10.1016\/j.semarthrit.2017.10.010_bib27","first-page":"S118","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib28","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/rheumatology\/ken441","article-title":"Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis","volume":"48","author":"Harris-Love","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib29","series-title":"Muscles Testing and Function with Posture and Pain","author":"Kendall FP","year":"2005"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/J006v26n03_02","article-title":"Intra-rater and inter-rater reliability of the 10-point Manual Muscle Test (MMT) of strength in children with juvenile idiopathic inflammatory myopathies (JIIM)","volume":"26","author":"Jain","year":"2006","journal-title":"Phys Occup Ther Pediatr"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib31","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/BOR.0b013e32834ba787","article-title":"Clinical trials roundup in idiopathic inflammatory myopathies","volume":"23","author":"Mann","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib32","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00415-011-5907-2","article-title":"Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies","volume":"258","author":"Stubgen","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib33","doi-asserted-by":"crossref","first-page":"369432","DOI":"10.1155\/2012\/369432","article-title":"The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy","volume":"2012","author":"De Paepe","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib34","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/rheumatology\/ken074","article-title":"Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis","volume":"47","author":"Riley","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000114036","article-title":"Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate","volume":"59","author":"Hengstman","year":"2008","journal-title":"Eur Neurol"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib36","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/rheumatology\/keh062","article-title":"Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1","volume":"43","author":"Sprott","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib37","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.22477","article-title":"A randomized, pilot trial of etanercept in dermatomyositis","volume":"70","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000079547","article-title":"Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up","volume":"52","author":"Hengstman","year":"2004","journal-title":"European neurology"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib39","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3109\/s10165-006-0523-1","article-title":"Polymyositis associated with infliximab treatment for rheumatoid arthritis","volume":"16","author":"Urata","year":"2006","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.10.010_bib40","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/rheumatology\/keg388","article-title":"Polymyositis associated with infliximab treatment for rheumatoid arthritis","volume":"42","author":"Musial","year":"2003","journal-title":"Rheumatology (Oxford)"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217303384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217303384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:57:06Z","timestamp":1758733026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017217303384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0049017217303384"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.10.010","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}